Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-   A4209 NSC 207895 (XI-006)Target: MDMXSummary: MDMX inhibitor,anti-cancer agent A4209 NSC 207895 (XI-006)Target: MDMXSummary: MDMX inhibitor,anti-cancer agent
-   A4213 Necrostatin-132 CitationTarget: RIP kinasesSummary: RIP1 inhibitor A4213 Necrostatin-132 CitationTarget: RIP kinasesSummary: RIP1 inhibitor
-   A4224 GDC-01522 CitationTarget: Inhibitor of apoptosis proteins (IAP)Summary: IAP antagonist,potent amd samll-molecule A4224 GDC-01522 CitationTarget: Inhibitor of apoptosis proteins (IAP)Summary: IAP antagonist,potent amd samll-molecule
-   A4237 Amuvatinib (MP-470, HPK 56)Summary: Tyrosine kinase inhibitor A4237 Amuvatinib (MP-470, HPK 56)Summary: Tyrosine kinase inhibitor
-   A4202 RITA (NSC 652287)Summary: Mdm2-p53 interaction and p53 ubiquitination blocking A4202 RITA (NSC 652287)Summary: Mdm2-p53 interaction and p53 ubiquitination blocking
-   A4194 Obatoclax mesylate (GX15-070)1 CitationTarget: Bcl-2Summary: Potent Bcl-2 inhibitor A4194 Obatoclax mesylate (GX15-070)1 CitationTarget: Bcl-2Summary: Potent Bcl-2 inhibitor
-   A1921 Z-DQMD-FMK3 CitationTarget: CaspasesSummary: Caspase-3 inhibitor,cell-permeable A1921 Z-DQMD-FMK3 CitationTarget: CaspasesSummary: Caspase-3 inhibitor,cell-permeable
-   A3278 Nonivamide (Capsaicin Analog)1 CitationTarget: TRP ChannelSummary: TRPV1 receptor agonist A3278 Nonivamide (Capsaicin Analog)1 CitationTarget: TRP ChannelSummary: TRPV1 receptor agonist
-   A4475 TLQP 21Summary: VGF-derived peptide A4475 TLQP 21Summary: VGF-derived peptide
-   B5892 Nolatrexed (AG-337)Summary: Non-classical thymidylate synthase inhibitor B5892 Nolatrexed (AG-337)Summary: Non-classical thymidylate synthase inhibitor

